Treatment with selective serotonin reuptake inhibitors for enhancing wound healing

Medical Hypotheses

Volumn 63, Issue 1, 2004, Pages 103-109

  Malinin, Alex ^a   Oshrine, Benjamin ^a   Serebruany, Victor ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; ANTIDEPRESSANT AGENT; CANCER GROWTH FACTOR; CITALOPRAM; CLOMIPRAMINE; COLONY STIMULATING FACTOR; CYTOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FLUOXETINE; GROWTH FACTOR; IMIPRAMINE; KETANSERIN; PAROXETINE; PLATELET DERIVED GROWTH FACTOR; PROTEIN DERIVATIVE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANGIOGENESIS; ANXIETY; CELL INTERACTION; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; HIGH RISK POPULATION; HISTAMINE RELEASE; HUMAN; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN INDUCTION; REVIEW; SKIN PROTECTION; STATISTICAL SIGNIFICANCE; THROMBOCYTE ACTIVATION; WOUND HEALING;

EID: 3042803316     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.10.021     Document Type: Article

References (73)

1. Jian B., Xu J., Connolly J., Savani R.C., et al. Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am. J. Pathol. 161:2002;2111-2121
2. Eison A.S., Mullins U.L. Regulation of central 5-HT2A receptors: a review of in vivo studies. Behav. Brain Res. 73:1996;177-181
3. Leonard B.E. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs. 43(Suppl 2):1992;3-9
4. 2+ mobilization in platelets. Eur. J. Pharmacol. 288:1995;373-377
5. Maes M. The immunoregulatory effects of antidepressants. Hum. Psychopharmacol. 16:2001;95-103
6. Mani H., Sidhu G.S., Kumari R., et al. Curcumin differentially regulates TGF-beta1, its receptors and nitric oxide synthase during impaired wound healing. Biofactors. 16:2002;29-43
7. Lerman O.Z., Galiano R.D., Armour M., Levine J.P., Gurtner G.C. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am. J. Pathol. 162:2003;303-312
8. Clarke M.Y., Brayer J., Heintz K., et al. Differential absorption and distribution of epidermal growth factor and insulin-like growth factor in diabetic NOD mice. J. Diabetes Complications. 15:2001;103-111
9. Altavilla D., Saitta A., Cucinotta D., et al. Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse. Diabetes. 50:2001;667-674
10. Koveker G.B. Growth factors in clinical practice. Int. J. Clin Pract. 54:2000;590-593
11. Komarcevic A. The modern approach to wound treatment. Med. Pregl. 53:2000;363-368
12. Bryant M., Drew G.M., Houston P., et al. Tissue repair with a therapeutic transcription factor. Hum. Gene Ther. 11:2002;2143-2158
13. Vogt P.M., Lehnhardt M., Wagner D., Steinau H.U. Growth factors and insulin-like growth factor binding proteins in acute wound fluid. Growth Horm. IGF Res. (Suppl B):1998;107-109
14. Bayat A., Bock O., Mrowietz U., et al. Genetic susceptibility to keloid disease and hypertrophic scarring: transforming growth factor beta1 common polymorphisms and plasma levels. Plast. Reconstr. Surg. 111:2003;535-543
15. Takeuchi M., Tredget E.E., Scott P.G., et al. The antifibrogenic effects of liposome-encapsulated IFN-alpha2b cream on skin wounds. J. Interferon Cytokine Res. 19:1999;1413-1419
16. Most D., Efron D.T., Shi H.P., et al. Characterization of incisional wound healing in inducible nitric oxide synthase knockout mice. Surgery. 132:2002;866-876
17. Schwentker A., Vodovotz Y., Weller R., Billiar T.R. Nitric oxide and wound repair: role of cytokines? Nitric Oxide. 7:2002;1-10
18. Mossner R., Daniel S., Schmitt A., et al. Modulation of serotonin transporter function by interleukin-4. Life Sci. 68:2001;873-880
19. Yang M., Srikiatkhachorn A., Anthony M., Chong B.H. Serotonin stimulates megakaryocytopoiesis via the 5-HT2 receptor. Blood Coagul. Fibrinolysis. 7:1996;127-133
20. Grewal J.S., Mukhin Y.V., Garnovskaya M.N., et al. Serotonin 5-HT2A receptor induces TGF-beta1 expression in mesangial cells via ERK: proliferative and fibrotic signals. Am. J. Physiol. 276:1996;922-930
21. Kasho M., Sakai M., Sasahara T., Anami Y., et al. Serotonin enhances the production of type IV collagen by human mesangial cells. Kidney Int. 54:1998;1083-1092
22. Mullaney P., Curren B., Collum L., Kilfeather S. Fibroblast and endothelial outgrowth from human Tenon's explants: inhibition of fibroblast growth by 5HT receptor antagonism. Res. Commun. Chem. Pathol. Pharmacol. 74:1991;201-213
23. Bueno L., Fioramonti J. Effects of inflammatory mediators on gut sensitivity. Can. J. Gastroenterol. 13(Suppl A):1999;42A-46A
24. Zhang Y., Gao X., Yang Z.L., et al. Expression of 5-HT (1A) receptor mRNA in rat nucleus raphe magnus neurons after peripheral inflammation. Brain Res. 887:2000;465-468
25. Alstergren P, Ernberg M, Kopp S, et al. TMJ pain in relation to circulating neuropeptide Y, serotonin, and interleukin-1 beta in rheumatoid arthritis. J. Orofac. Pain 13:49-55
26. Mossner R., Heils A., Stober G., et al. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem. Int. 33:1998;251-254
27. Abdouh M., Storring J.M., Riad M., et al. Transcriptional mechanisms for induction of 5-HT1A receptor mRNA and protein in activated B and T lymphocytes. J. Biol. Chem. 276:2001;4382-4388
28. Laberge S., Cruikshank W.W., Beer D.J., Center D.M. Secretion of IL-16 (lymphocyte chemoattractant factor) from serotonin-stimulated CD8+ T cells in vitro. J. Immunol. 156:1996;310-315
29. Young M.R., Matthews J.P. Serotonin regulation of T-cell subpopulations and of macrophage accessory function. 84:1995;148-152
30. Polanski M., Vermeulen M.W., Wu J., Karnovsky M.L. Muramyl dipeptide mimicry in the regulation of murine macrophage activation by serotonin. Int. J. Immunopharmacol. 17:1995;225-232
31. Sternberg E.M., Wedner H.J., Leung M.K., Parker C.W. Effect of serotonin (5-HT) and other monoamines on murine macrophages: modulation of interferon-gamma induced phagocytosis. J. Immunol. 138:1987;4360-4365
32. Los G., De Weger R.A., Van den Berg D.T., et al. Macrophage infiltration in tumors and tumor-surrounding tissue: influence of serotonin and sensitized lymphocytes. Cancer. Immunol. Immunother. 26:1988;145-152
33. Li Z., Niwa Y., Rokutan K., Nakaya Y. Expression of endothelin-1 in macrophages and mast cells in hyperplastic human tonsils. FEBS Lett. 457:1999;381-384
34. Simonson M.S., Herman W.H., Knauss T.C., et al. Macrophages - but not T-cell-derived cytokines stimulate endothelin-1 secretion by endothelial cells. Transplant. Proc. 31:1999;806-807
35. Obara K., Koide M., Ishikawa T., et al. Protein kinase C delta but not PKC epsilon activity is involved in contractile potentiation by endothelin-1 in the porcine coronary artery. J. Cardiovasc. Pharmacol. 36:2000;S120-S121
36. Fitzgerald L.W., Burn T.C., Brown B.S., et al. Possible role of valvular serotonin 5-HT (2B) receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57:2000;75-81
37. Pakala R., Willerson J.T., Benedict C.R. Mitogenic effect of serotonin on vascular endothelial cells. Circulation. 90:1994;1919-1926
38. Pakala R., Sheng W.L., Benedict C.R. Serotonin fails to induce proliferation of endothelial cells preloaded with eicosapentaenoic acid and docosahexaenoic acid. Atherosclerosis. 145:1999;137-146
39. Lee S.L., Wang W.W., Moore B.J., Fanburg B.L. Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. Circ. Res. 68:1991;1362-1368
40. Massey M.F., Davies M.G., Svendsen E., et al. Reduction of experimental vein graft intimal hyperplasia by ketanserin. J. Surg. Res. 54:1993;530-538
41. Lenz G., Goncalves D., Luo Z., et al. Extracellular ATP stimulates an inhibitory pathway towards growth factor-induced cRaf-1 and MEKK activation in astrocyte cultures. J. Neurochem. 77:2001;1001-1009
42. Seuwen K., Magnaldo I., Pouyssegur J. Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. Nature. 335:1988;254-256
43. Lee S.L., Wang W.W., Finlay G.A., Fanburg B.L. Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am. J. Physiol. 277:1999;L282-L291
44. Fitzgerald L.W., Burn T.C., Brown B.S., et al. Possible role of valvular serotonin 5-HT (2B) receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57:2002;75-81
45. Gedevanishvili M.D., Tsutsunava L.E., Malazoniia N.A. Serotonin independently stimulates fibroblast adhesion and multiplication in culture. Tsitologiia. 24:1982;224-226
46. Kihara H., Hirose K., Koganei H., et al. AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats. J. Cardiovasc. Pharmacol. 35:2000;523-530
47. Konishi M., Sakakura M., Tsushima N. Effects of ketanserin on microhemodynamics and hemorheology in patients with essential hypertension. Cardiovasc. Drugs Ther. 4(Suppl 1):1990;101-104
48. Knypl K., Wocial B., Berent H., et al. Influence of chronic ketanserin therapy on blood pressure and certain humoral and metabolic factors in patients with mild to moderate primary essential hypertension. Pol. Arch. Med. Wewn. 90:1993;95-104
49. Du W.M., Miao C.Y., Liu J.G., et al. Effects of long-term treatment with ketanserin on blood pressure variability and end-organ damage in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 41:2003;233-239
50. Belch J.J., Ho M. Pharmacotherapy of Raynaud's phenomenon. Drugs. 52:1996;682-695
51. Pope J., Fenlon D., Thompson A., et al. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst. Rev. 2:2002;CD000954
52. Janssen P.A., Janssen H., Cauwenbergh G., et al. Use of topical ketanserin in the treatment of skin ulcers: a double-blind study. J. Am. Acad. Dermatol. 21:1989;85-90
53. Roelens P. Double-blind placebo-controlled study with topical 2% ketanserin ointment in the treatment of venous ulcers. Dermatologica. 178:1989;98-102
54. Apelqvist J., Castenfors J., Larsson J., et al. Ketanserin in the treatment of diabetic foot ulcer with severe peripheral vascular disease. Int. Angiol. 9:1990;120-124
55. Lawrence C.M., Matthews J.N., Cox N.H. The effect of ketanserin on healing of fresh surgical wounds. Br. J. Dermatol. 132:1995;580-586
56. Cirillo P., Golino P., Ragni M., et al. Activated platelets and leucocytes cooperatively stimulate smooth muscle cell proliferation and proto-oncogene expression via release of soluble growth factors. Cardiovasc. Res. 43:1999;210-218
57. de Montigny C., Chaput Y., Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. J. Clin. Psychiatry. 51(Suppl B):1990;4-8
58. Rickels K., Schweizer E. Clinical overview of serotonin reuptake inhibitors. J. Clin. Psychiatry. 51(Suppl B):1990;9-12
59. Bakish D., Cavazzoni P., Chudzik J., et al. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biol. Psychol. 41:1997;184-190
60. Maguire K., Tuckwell V., Pereira A., et al. Significant correlation between 14C-5-HT uptake by and 3H-paroxetine binding to platelets from healthy volunteers. Biol. Psychiatry. 34:1993;356-360
61. Butler J., Leonard B.E. The platelet serotonergic system in depression and following sertraline treatment. Int. J. Clin. Psychopharmacol. 3:1988;343-347
62. Phillips O.M., Wood K.M., Williams D.C. Kinetics of the interaction of sertraline with the human platelet plasma membrane 5-hydroxytryptamine carrier. Eur. J. Pharmacol. 146:1988;299-306
63. Kubera M., Lin A.H., Kenis G., Bosmans E., et al. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/ interleukin-10 production ratio. J. Clin. Psychopharmacol. 21:2001;199-206
64. Oben J.A., Yang S., Lin H., et al. Acetylcholine promotes the proliferation and collagen gene expression of myofibroblastic hepatic stellate cells. Biochem. Biophys. Res. Commun. 300:2003;172-177
65. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20:2000;9104-9110
66. Martinez-de Jesus F.R., Morales-Guzman M., Castaneda M., et al. Randomized single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers. Arch. Med. Res. 28:1997;95-99
67. Kubera M., Simbirtsev A., Mathison R., Maes M. Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice. Psychiatry Res. 96:2000;255-266
68. Moulin V., Lawny F., Barritault D., Caruelle J.P. Platelet releasate treatment improves skin healing in diabetic rats through endogenous growth factor secretion. Cell. Mol. Biol. 44:1998;961-971
69. Powell C.C., Rohrer M.J., Barnard M.R., et al. Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation. J. Vasc. Surg. 30:1999;844-851
70. Serebruany V.L., Gurbel P.A., O'Connor C.M. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharm. Res. 43:2001;453-462
71. Serebruany V.L., O'Connor C.M., Gurbel P.A. Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. Am. J. Cardiol. 87:2001;1398-1400
72. Glassman A.H., O'Connor C.M., Califf R.M., et al. Sertraline treatment of major depression in patients with acute myocardial infarction or unstable angina. JAMA. 288:2002;701-709
73. ® on platelet/endothelial biomarkers in depressed patients after acute coronary events: sertraline anti-depressant heart attack randomized trial (SADHART platelet substudy) Circulation. 108:2003;939-944